DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelo id Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome Interventions: Biological: Antineoplastic Antibody-Drug Conjugate; Drug: Azacitidine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Biological: Filgrastim; Drug: Leucovorin; Drug: Mesna; Drug: Methotrexate; Drug: Posaconazole; Drug: Prednisone; Biolog ical: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Voriconazole Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Dexamethasone | Filgrastim | Leukemia | Methotrexate | Neulasta | Neupogen | Prednisone | Research | Rituxan